Samsung Bioepis Showcases Denosumab Data
Firm Publishes Phase I And Phase III Results For SB16 Proposed Biosimilar To Prolia
Samsung Bioepis has reported positive Phase I and Phase III trial results for its SB16 proposed denosumab biosimilar to Prolia.
